- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Fredun Pharmaceuticals has released its standalone financial results for the quarter and half-year ended September 30, 2025, as approved by its Board. For the quarter, total income from operations stood at ₹145.29 Cr, with a net profit after tax of ₹9.73 Cr and basic EPS of ₹20.61. For the half-year, total income was ₹265.15 Cr, reporting a net profit after tax of ₹16.50 Cr and basic EPS of ₹34.94. These figures, providing a snapshot of the company's recent performance, are available on the stock exchange and company websites.